Welcome to dermRounds Dermatology Network!
Welcome to dermRounds - based on tradition of "Dermatology Rounds," created by dermatologists, this is a social and professional networking site dedicated to connecting dermatologists, residents, fellows, other physicians, health professionals, industry leaders, and anyone who is in the field of dermatology!
You can use dermRounds to:
> Connect: Keep in touch with alumni from residency, old friends from AAD, search for the dream private practice job, find an industry contact
> Collaborate: Share interesting cases, find a new research collaboration
> Get answers: Ask the community about a case, question, or latest industry news
AND, above all, sharing one's interests, expertise, & connections with others. dermRounds will most rapidly improve with the help of the people who use it. Spread the word too and invite a friend or colleague!
More dermatology news!
Novartis has announced that the European Commission (EC) has approved the use of Xolair® as an add-on therapy for the treatment of chronic spontaneous urticaria (CSU) in adult and adolescent (12 years and above) patients, who do not respond to the current mainstay of therapy, H1 antihistamines. The approved dose in CSU is 300 mg administered by subcutaneous injection once every four weeks.
People who had nonmelanoma skin cancer (NMSC) were at increased risk for subsequently developing melanoma and 29 other cancer types, and this association was much higher for those under 25 years of age, according to a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.NMSC is the most common type of skin cancer.
Researchers at the National Institutes of Health (NIH) have identified a new genetic syndrome characterized by a constellation of health problems, including severe allergy, immune deficiency, autoimmunity and motor and neurocognitive impairment.
Naturally occurring electricity in our cells is key to how our bodies function, and that includes the healing of wounds.Hard-to-heal wounds, like diabetic ulcers, fester because of insufficient blood supply at the wound site.
Journal of Drugs in Dermatology (JDD) has released a clinical study highlighting the efficacy of Triple Protection Factor Broad Spectrum Sunscreen, TPF 50, to prevent skin sun damage and Non-Melanoma Skin Cancer (NMSC). In this head-to-head comparison study, investigators Enzo Emanuele MD, PhD, James M.